Cellerix is a biotechnology company developing therapies based on adult stem cells.
Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 11, 2009 | Series B | €27M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Biopartners Capital | — | Series B |